Amicus Therapeutics (NASDAQ:FOLD) Downgraded by Wall Street Zen to Hold

Key Points

• Amicus Therapeutics (NASDAQ:FOLD) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating, indicating a cautious outlook on the stock.
• Despite the downgrade, several research firms have recently issued upgrades, with Morgan Stanley rating the stock as "overweight" and Zacks Research rating it as a "strong-buy".
• The company's stock is currently trading at $8.04, reflecting a market cap of $2.48 billion, with a 52-week range of $5.51 to $12.65.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Saturday.

Several other research firms have also weighed in on FOLD. Morgan Stanley upgraded Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a report on Thursday, July 17th. Zacks Research upgraded Amicus Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Monday, October 6th. Needham & Company LLC upgraded Amicus Therapeutics from a "hold" rating to a "buy" rating and set a $14.00 target price for the company in a report on Thursday, September 18th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Amicus Therapeutics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $15.88.

Amicus Therapeutics Trading Down 0.9%

Shares of NASDAQ FOLD opened at $8.04 on Friday. The stock has a market cap of $2.48 billion, a price-to-earnings ratio of -66.99 and a beta of 0.56. The business has a 50 day simple moving average of $7.88 and a 200 day simple moving average of $6.90. Amicus Therapeutics has a 52 week low of $5.51 and a 52 week high of $12.65. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Diversified Trust Co lifted its holdings in shares of Amicus Therapeutics by 2.2% during the first quarter. Diversified Trust Co now owns 83,542 shares of the biopharmaceutical company's stock worth $682,000 after buying an additional 1,784 shares during the last quarter. Tempus Wealth Planning LLC lifted its holdings in shares of Amicus Therapeutics by 7.2% during the first quarter. Tempus Wealth Planning LLC now owns 29,513 shares of the biopharmaceutical company's stock worth $241,000 after buying an additional 1,990 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Amicus Therapeutics by 2.8% during the second quarter. CANADA LIFE ASSURANCE Co now owns 83,764 shares of the biopharmaceutical company's stock worth $480,000 after buying an additional 2,263 shares during the last quarter. Stephens Inc. AR lifted its holdings in shares of Amicus Therapeutics by 27.4% during the first quarter. Stephens Inc. AR now owns 13,655 shares of the biopharmaceutical company's stock worth $111,000 after buying an additional 2,938 shares during the last quarter. Finally, Osaic Holdings Inc. lifted its holdings in shares of Amicus Therapeutics by 450.1% during the second quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 3,358 shares during the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.